BRPI0407140A - Droga terapêutica para vìrus - Google Patents

Droga terapêutica para vìrus

Info

Publication number
BRPI0407140A
BRPI0407140A BR0407140-9A BRPI0407140A BRPI0407140A BR PI0407140 A BRPI0407140 A BR PI0407140A BR PI0407140 A BRPI0407140 A BR PI0407140A BR PI0407140 A BRPI0407140 A BR PI0407140A
Authority
BR
Brazil
Prior art keywords
viruses
present
hcv
pharmaceutical composition
therapeutic drug
Prior art date
Application number
BR0407140-9A
Other languages
English (en)
Inventor
Masahiro Aoki
Hideyuki Kato
Masayuki Sudoh
Takuo Tsukuda
Miyako Masubuchi
Kenichi Kawasaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0407140A publication Critical patent/BRPI0407140A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DROGA TERAPêUTICA PARA VìRUS". A presente invenção refere-se a uma composição farmacêutica para a prevenção ou para o tratamento de doenças infecciosas virais. Os compostos da presente invenção possuem atividade anti-HCV extremamente potente e efeitos inibidores do crescimento do HCV e uma vez que demonstram ainda somente uma citotoxicidade suave in vivo, uma composição farmacêutica contendo o composto da presente invenção é extremamente útil como um agente preventivo/terapêutico anti-HCV.
BR0407140-9A 2003-02-12 2004-02-12 Droga terapêutica para vìrus BRPI0407140A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034056 2003-02-12
JP2003272420 2003-07-09
PCT/JP2004/001498 WO2004071503A1 (ja) 2003-02-12 2004-02-12 ウイルス治療薬

Publications (1)

Publication Number Publication Date
BRPI0407140A true BRPI0407140A (pt) 2006-02-07

Family

ID=32871168

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407140-9A BRPI0407140A (pt) 2003-02-12 2004-02-12 Droga terapêutica para vìrus

Country Status (15)

Country Link
US (2) US7776918B2 (pt)
EP (1) EP1593378B1 (pt)
JP (1) JP3921227B2 (pt)
KR (1) KR101071014B1 (pt)
AU (1) AU2004211850B2 (pt)
BR (1) BRPI0407140A (pt)
CA (1) CA2515370C (pt)
IL (1) IL169551A (pt)
MX (1) MXPA05008507A (pt)
MY (1) MY141506A (pt)
NO (1) NO20053348L (pt)
NZ (1) NZ542250A (pt)
RU (1) RU2350600C2 (pt)
TW (1) TWI335219B (pt)
WO (1) WO2004071503A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000294A (es) 2003-07-09 2006-04-18 Chugai Pharmaceutical Co Ltd Compuestos que tienen actividad contra el virus de la hepatitis c y procedimiento para producirlo.
JP2006077004A (ja) * 2004-08-11 2006-03-23 Chugai Pharmaceut Co Ltd 抗ｈｃｖ作用を有する化合物およびそれを含む医薬組成物
US8183005B1 (en) 2004-08-11 2012-05-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agents for treating HCV infections
JPWO2006088071A1 (ja) * 2005-02-17 2008-07-03 中外製薬株式会社 抗ｈｃｖ作用を有する化合物の製造方法およびその中間体
WO2007000994A1 (ja) * 2005-06-28 2007-01-04 Chugai Seiyaku Kabushiki Kaisha 抗ｈｃｖ作用を有する化合物の製造方法
JPWO2007132882A1 (ja) 2006-05-16 2009-09-24 財団法人 東京都医学研究機構 Ｈｃｖ感染症を治療または予防するための医薬組成物
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
EP2368989A4 (en) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd OLIGORIBONUCLEOTID- BZW. PEPTID NUCLEIC ACID TO INHIBIT THE ACTIVITY OF HEPATITIS C VIRUS
JP2013121935A (ja) 2011-12-12 2013-06-20 Institute Of Microbial Chemistry 化合物、及び不斉合成反応
EP2886530A4 (en) 2012-08-17 2016-01-27 Chugai Pharmaceutical Co Ltd ORAL ADMINISTRATIVE VIRIDIDEIN DERIVATIVE WITH ANTI-HCV ACTIVITY
JP5933867B1 (ja) * 2016-03-28 2016-06-15 公益財団法人微生物化学研究会 化合物、及び不斉合成反応
CN114105855B (zh) * 2020-08-31 2024-03-15 中国科学院大连化学物理研究所 一种在吲哚c2位引入异戊烯基的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU770012A1 (ru) * 1979-05-21 1982-01-23 Ордена Трудового Красного Знамени Институт Высокомолекулярных Соединений Ан Ссср D,L-или L-N-метакрилоилтриптофан в качестве мономера дл получени полимеров с ковалентно присоединенными триптофановыми группами
US5364948A (en) 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
EP0526936A3 (en) * 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
JP4091130B2 (ja) * 1997-06-09 2008-05-28 タカラバイオ株式会社 生理活性物質ｔｋｒ２４４９類、製造方法及び微生物

Also Published As

Publication number Publication date
KR101071014B1 (ko) 2011-10-06
CA2515370A1 (en) 2004-08-26
CA2515370C (en) 2012-01-17
NO20053348L (no) 2005-09-12
MXPA05008507A (es) 2005-10-20
EP1593378A1 (en) 2005-11-09
EP1593378A4 (en) 2009-05-06
MY141506A (en) 2010-05-14
NZ542250A (en) 2008-12-24
IL169551A (en) 2011-10-31
AU2004211850B2 (en) 2009-06-04
TWI335219B (en) 2011-01-01
US7776918B2 (en) 2010-08-17
JPWO2004071503A1 (ja) 2006-06-01
RU2005128297A (ru) 2006-02-27
NO20053348D0 (no) 2005-07-11
KR20050098929A (ko) 2005-10-12
AU2004211850A1 (en) 2004-08-26
US20060217434A1 (en) 2006-09-28
RU2350600C2 (ru) 2009-03-27
WO2004071503A1 (ja) 2004-08-26
TW200501940A (en) 2005-01-16
US20100274026A1 (en) 2010-10-28
JP3921227B2 (ja) 2007-05-30
HK1095036A1 (zh) 2007-04-20
EP1593378B1 (en) 2013-09-25
AU2004211850A2 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
UY27333A1 (es) Nucleótidos 4` sustituidos
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BRPI0506705A (pt) composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
BR0310006A (pt) Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
BRPI0407140A (pt) Droga terapêutica para vìrus
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
EP1201236A4 (en) MEDICAL COMPOSITIONS FOR PREVENTING THE TREATMENT OF VIRAL MYOCASCHITIS
BRPI0407178A (pt) Composição farmacêutica osteogênica
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
JP2006507295A5 (pt)
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
WO2005095345A3 (en) Heteroaryl guanidines as inhibitors of viral replication
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
DE502005008500D1 (de) Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
HUP0204180A2 (hu) Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére
WO2006131566A3 (en) Oral ribavirin pharmaceutical compositions
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.